Cargando…

5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma

BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxy...

Descripción completa

Detalles Bibliográficos
Autores principales: Barazeghi, Elham, Gill, Anthony J., Sidhu, Stan, Norlén, Olov, Dina, Roberto, Palazzo, F. Fausto, Hellman, Per, Stålberg, Peter, Westin, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789293/
https://www.ncbi.nlm.nih.gov/pubmed/26973719
http://dx.doi.org/10.1186/s13148-016-0197-2
_version_ 1782420829895655424
author Barazeghi, Elham
Gill, Anthony J.
Sidhu, Stan
Norlén, Olov
Dina, Roberto
Palazzo, F. Fausto
Hellman, Per
Stålberg, Peter
Westin, Gunnar
author_facet Barazeghi, Elham
Gill, Anthony J.
Sidhu, Stan
Norlén, Olov
Dina, Roberto
Palazzo, F. Fausto
Hellman, Per
Stålberg, Peter
Westin, Gunnar
author_sort Barazeghi, Elham
collection PubMed
description BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p < 0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels. A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of 5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth. CONCLUSIONS: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth regulatory role of TET1 in parathyroid tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0197-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4789293
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47892932016-03-14 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma Barazeghi, Elham Gill, Anthony J. Sidhu, Stan Norlén, Olov Dina, Roberto Palazzo, F. Fausto Hellman, Per Stålberg, Peter Westin, Gunnar Clin Epigenetics Research BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p < 0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels. A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of 5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth. CONCLUSIONS: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth regulatory role of TET1 in parathyroid tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0197-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-12 /pmc/articles/PMC4789293/ /pubmed/26973719 http://dx.doi.org/10.1186/s13148-016-0197-2 Text en © Barazeghi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Barazeghi, Elham
Gill, Anthony J.
Sidhu, Stan
Norlén, Olov
Dina, Roberto
Palazzo, F. Fausto
Hellman, Per
Stålberg, Peter
Westin, Gunnar
5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title_full 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title_fullStr 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title_full_unstemmed 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title_short 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
title_sort 5-hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789293/
https://www.ncbi.nlm.nih.gov/pubmed/26973719
http://dx.doi.org/10.1186/s13148-016-0197-2
work_keys_str_mv AT barazeghielham 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT gillanthonyj 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT sidhustan 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT norlenolov 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT dinaroberto 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT palazzoffausto 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT hellmanper 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT stalbergpeter 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma
AT westingunnar 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma